Amgen's new leukemia drug Blincyto costs $178,000 for two courses of the treatment.» Read More
Oct 24- Amgen Inc, one of the world's largest biotechnology companies, will unveil next week its first strategy update since early 2013, but few expect a major shift like the split-up recently proposed by Daniel Loeb's Third Point hedge fund. In a letter to investors on Tuesday, Loeb said Amgen has "all the hallmarks of a hidden value situation" and should divide...
Global equity strategists pick out U.S. sectors and stocks that could be affected in Friday's trading session on the back of the NY Ebola case.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.
Big name investors like Dan Loeb and David Einhorn helped raise $6 million to fight poverty at a charity event in New York City.
BOSTON, Oct 21- Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent. "Our own extensive diligence suggests that a breakup of Amgen is feasible and that purported constraints such as tax strategy and supply...
There are 12 stocks that are up more than 10,000% since the 1987 Black Monday crash, reports USA Today.
Hedge fund manager Dan Loeb recommended Amgen's stock Tuesday, causing shares to rise on the news.
WASHINGTON, Oct 16- Medicine costs would rise if draft proposals in a Pacific Rim trade pact come into force, health and consumer rights advocates said on Thursday after the release of a leaked negotiating text. The TPP's 12 members range from the United States and Japan to Malaysia and Vietnam, where equitable access to medicine is a priority, and Australia and...
Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...
Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. While the FDA is not obligated to accept the recommendations of the panel, it typically does so. The FDA staff based its recommendation on the review of the data from this study,...
Take a look at some of Wednesday's midday movers:
Oct 8- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease. "We remain bullish about AMGN's biosimilar prospects given the manufacturing expertise which would likely be key for success in biosimilar competition," Deutsche...
Oct 8- Amgen Inc said its experimental drug to treat a type of skin disease compared favorably with AbbVie Inc's Humira, a commonly prescribed drug for the condition, in a late-stage trial. The drug, ABP 501, was being tested in patients with plaque psoriasis, a skin disease caused by dysfunction of the immune system that leads to painful, itchy red patches.
NEW YORK, Sept 29- U.S. securities regulators can move forward with a lawsuit accusing two Dubai residents of making $3.7 million through insider trading in Onyx Pharmaceuticals Inc and another biotechnology company, a Manhattan federal judge ruled on Monday.
A report said Devon Energy, Anadarko Petroleum and Facebook are among the multinational S&P 100 corporations hit with the highest tax rates in 2013.
Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
NEW YORK, Sept 12- Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector. Vertex Pharmaceuticals lost 1.2 percent to $93.10 while Amgen was off 0.9 percent to $137.64 and Regeneron Pharma lost 1 percent to $346.82.
*Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.
*Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.